Cited by 15,011Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of LifeVoice and Speech Disorders

The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, John F.·1983·Neurology

DOI 10.1212/wnl.33.11.1444

Open this paper in CoChat — free account

Abstract

One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.

Integrity signals

Registry

Crossref · 10.1212/wnl.33.11.1444

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

On the evaluation of disability in multiple sclerosis
Kurtzke, J. F. (1961) · Neurology · doi:10.1212/wnl.11.8.686 · Cited by 330
Further notes on disability evaluation in multiple sclerosis, with scale modifications
Kurtzke, J. F. (1965) · Neurology · doi:10.1212/wnl.15.7.654 · Cited by 309
A New Scale for Evaluating Disability in Multiple Sclerosis
Kurtzke, J. F. (1955) · Neurology · doi:10.1212/wnl.5.8.580 · Cited by 305
Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps.
Wood, P. (1980) · PubMed · Cited by 247
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
Kurtzke, J. F. (1970) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1970.tb05808.x · Cited by 156
A PROPOSAL FOR A UNIFORM MINIMAL RECORD OF DISABILITY IN MULTIPLE SCLEROSIS
Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05548.x · Cited by 127
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS 6. Clinical and Laboratory Findings at First Diagnosis
Kurtzke, J. F., Beebe, G. W., Nagler, B., Auth, T. L., Kurland, L. T., & Nefzger, M. D. (1972) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1972.tb07525.x · Cited by 68
THE SOCIO-ECONOMIC SCALE
Mellerup, E., Fog, T., Raun, N. E., Colville, P., de Rham, B., Hannah, B., & Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05549.x · Cited by 53
The effects of isoniazid on patients with multiple sclerosis; preliminary report.
Kurtzke, J. F., & Berlin, L. (1954) · PubMed · doi:10.1164/art.1954.70.4.577 · Cited by 23
ACUTE RESPIRATORY FAILURE IN MULTIPLE SCLEROSIS AND ITS MANAGEMENT
Guthrie, T. C., Kurtzke, J. F., & BERLIN, L. (1952) · Annals of Internal Medicine · doi:10.7326/0003-4819-37-6-1197 · Cited by 20

Show all 13 references

Sorted by citations

Items 701–800 of 1,135

Disability as an outcome in MS clinical trials
Ebers, G. C., Heigenhauser, L., Däumer, M., Lederer, C., & Noseworthy, J. H. (2008) · Neurology · doi:10.1212/01.wnl.0000313034.46883.16 · Cited by 180
Evaluating Walking in Patients with Multiple Sclerosis
Béthoux, F., & Bennett, S. E. (2011) · International Journal of MS Care · doi:10.7224/1537-2073-13.1.4 · Cited by 180
Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study
Jacobsen, C., Hagemeier, J., Myhr, K., Nyland, H., Lode, K., Bergsland, N., Ramasamy, D. P., Dalaker, T. O., Larsen, J. P., Farbu, E., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306906 · Cited by 180
The natural history of primary progressive multiple sclerosis
Koch, M. W., Kingwell, E., Rieckmann, P., & Tremlett, H. L. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c5b47f · Cited by 192
Neuromuscular responses of patients with multiple sclerosis
Rice, C. L., Vollmer, T. L., & Bigland-Ritchie, B. (1992) · Muscle & Nerve · doi:10.1002/mus.880151011 · Cited by 180
Multiple Sclerosis: Magnetization Transfer MR Imaging of White Matter before Lesion Appearance on T2-weighted Images
Pike, G. B., Stefano, N. D., Narayanan, S., Worsley, K. J., Pelletier, D., Francis, G., Antel, J. P., & Arnold, D. L. (2000) · Radiology · doi:10.1148/radiology.215.3.r00jn02824 · Cited by 181
HLA-DPB1*0501-associated opticospinal multiple sclerosis: Clinical, neuroimaging and immunogenetic studies
Yamasaki, K. (1999) · Brain · doi:10.1093/brain/122.9.1689 · Cited by 180
Dietary interventions for multiple sclerosis
Farinotti, M., Vacchi, L., Simi, S., Pietrantonj, C. D., Brait, L., & Filippini, G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004192.pub3 · Cited by 180
Relationships between information processing, depression, fatigue and cognition in multiple sclerosis
DIAMOND, B., JOHNSON, S., KAUFMAN, M., & Graves, L. (2007) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2007.10.002 · Cited by 179
Clinical outcome measures in multiple sclerosis: A review
Inojosa, H., Schriefer, D., & Ziemssen, T. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102512 · Cited by 184
APOE genotype is a major predictor of long-term progression of disability in MS
Chapman, J., Vinokurov, S., Achiron, A., Karussis, D. M., Mitosek‐Szewczyk, K., Birnbaum, M., Michaelson, D. M., & Korczyn, A. D. (2001) · Neurology · doi:10.1212/wnl.56.3.312 · Cited by 179
Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype.
Pagani, E., Rocca, M. A., Gallo, A., Rovaris, M., Martinelli, V., Comi, G., & Filippi, M. (2005) · PubMed Central · Cited by 178
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
Gaetani, L., Höglund, K., Parnetti, L., Pujol-Calderón, F., Becker, B., Eusebi, P., Sarchielli, P., Calabresi, P., Filippo, M. D., Zetterberg, H., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0339-1 · Cited by 180
Costs and quality of life of multiple sclerosis in Spain
Kobelt, G., Berg, J., Lindgren, P., Izquierdo, G., Sánchez‐Soliño, O., Perez-Miranda, J., Casado, M. A., & Múltiple, A. E. D. E. (2006) · The European Journal of Health Economics · doi:10.1007/s10198-006-0381-y · Cited by 179
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS)
Nash, R. A., Hutton, G. J., Racke, M. K., Popat, U., Devine, S. M., Griffith, L. M., Muraro, P. A., Openshaw, H., Sayre, P. H., Stüve, O., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3780 · Cited by 177
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Cohen, J. A., Arnold, D. L., Comi, G., Bar‐Or, A., Gujrathi, S., Hartung, J. P., Cravets, M., Olson, A. D., Frohna, P., & Selmaj, K. W. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00018-1 · Cited by 177
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis
Cagol, A., Schaedelin, S. A., Baraković, M., Benkert, P., Todea, R., Rahmanzadeh, R., Galbusera, R., Lu, P., Weigel, M., Melie‐García, L., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1025 · Cited by 187
Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial
Cohen, J. A. (2001) · Archives of Neurology · doi:10.1001/archneur.58.6.961 · Cited by 177
Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis
Mattioli, F., Stampatori, C., Zanotti, D., Parrinello, G., & Capra, R. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.09.024 · Cited by 176
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes
Avolio, C., Ruggieri, M., Giuliani, F., Liuzzi, G. M., Leante, R., Riccio, P., Livrea, P., & Trojano, M. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00006-7 · Cited by 176
Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis
Savcı, S., Inal-Ince, D., Arıkan, H., Guclu‐Gunduz, A., Cetisli-Korkmaz, N., Armutlu, K., & Karabudak, R. (2005) · Disability and Rehabilitation · doi:10.1080/09638280500164479 · Cited by 176
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course
Portaccio, E., Magyari, M., Havrdová, E., Ruet, A., Brochet, B., Scalfari, A., Filippo, M. D., Tur, C., Montalbán, X., & Amato, M. P. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100977 · Cited by 196
Performance of the SF-36, SF-12, and RAND-36 Summary Scales in a Multiple Sclerosis Population
Nortvedt, M. W., Riise, T., Myhr, K., & Nyland, H. (2000) · Medical Care · doi:10.1097/00005650-200010000-00006 · Cited by 175
Clinical outcomes assessment in multiple sclerosis
Rudick, R. A., Fischer, J. S., Antel, J. P., Confavreux, C., Cutter, G., Ellison, G. W., LUBLIN, F. D., Miller, A., Petkau, J., Rao, S. M., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400321 · Cited by 176
Quantitative assessment of MRI lesion load in multiple sclerosis: A comparison of conventional spin-echo with fast fluidattenuated inversion recovery
Filippi, M., Baratti, C., Yousry, T. A., Horsfield, M. A., Mammì, S., Becker, C. R., Voltz, R., Spuler, S., Campi, A., Reiser, M., et al. (1996) · Brain · doi:10.1093/brain/119.4.1349 · Cited by 177
Cognitive impairment and cortical degeneration in neuromyelitis optica
Saji, E., Arakawa, M., Yanagawa, K., Toyoshima, Y., Yokoseki, A., Okamoto, K., Otsuki, M., Akazawa, K., Kakita, A., Takahashi, H., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23721 · Cited by 176
The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction
Sanfilipo, M. P., Benedict, R. H. B., Sharma, J., Weinstock‐Guttman, B., & Bakshi, R. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.008 · Cited by 175
Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis
Ciccarelli, O., Wheeler‐Kingshott, C. A. M. G., McLean, M. A., Cercignani, M., Wimpey, K., Miller, D. H., & Thompson, A. J. (2007) · Brain · doi:10.1093/brain/awm152 · Cited by 177
Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM
Bodini, B., Khaleeli, Z., Cercignani, M., Miller, D. H., Thompson, A. J., & Ciccarelli, O. (2009) · Human Brain Mapping · doi:10.1002/hbm.20713 · Cited by 175
High‐Resolution Fluorodeoxyglucose Positron Emission Tomography Shows Both Global and Regional Cerebral Hypometabolism in Multiple Sclerosis
Bakshi, R., Miletich, R. S., Kinkel, P. R., Emmet, M. L., & Kinkel, W. R. (1998) · Journal of Neuroimaging · doi:10.1111/jon199884228 · Cited by 173
Grey matter loss in relapsing-remitting multiple sclerosis: A voxel-based morphometry study
Prinster, A., Quarantelli, M., Orefice, G., Lanzillo, R., Brunetti, A., Mollica, C., Salvatore, E., Morra, V., Coppola, G., Vacca, G., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.08.034 · Cited by 189
Sexual function in women with advanced multiple sclerosis.
Hulter, B., & Lundberg, P. O. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.1.83 · Cited by 175
Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging
Silver, N. (1997) · Brain · doi:10.1093/brain/120.7.1149 · Cited by 175
Linomide in relapsing and secondary progressive MS
Noseworthy, J. H., Wolinsky, J. S., LUBLIN, F. D., Whitaker, J. N., Linde, A., Gjörstrup, P., Sullivan, H. C., & the North American Linomide Investigators (2000) · Neurology · doi:10.1212/wnl.54.9.1726 · Cited by 173
Genotype–Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures
Okuda, D. T., Srinivasan, R., Oksenberg, J. R., Goodin, D. S., Baranzini, S. E., Beheshtian, A., Waubant, E. L., Zamvil, S. S., Leppert, D., Qualley, P., et al. (2008) · Brain · doi:10.1093/brain/awn301 · Cited by 175
Age Related Multiple Sclerosis Severity Score: Disability ranked by age
Manouchehrinia, A., Westerlind, H., Kingwell, E., Zhu, F., Carruthers, R., Ramanujam, R., Ban, M., Glaser, A., Sawcer, S., Tremlett, H., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690618 · Cited by 174
A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging
Ciccarelli, O., Werring, D. J., Barker, G. J., Griffin, C., Wheeler‐Kingshott, C. A. M. G., Miller, D. H., & Thompson, A. J. (2003) · Journal of Neurology · doi:10.1007/s00415-003-0992-5 · Cited by 174
Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies
Franciotta, D. M., Martino, G., Zardini, E., Furlan, R., Bergamaschi, R., Andreoni, L., & Cosi, V. E. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00261-2 · Cited by 174
Effect of Smoking Cessation on Multiple Sclerosis Prognosis
Ramanujam, R., Hedström, A. K., Manouchehrinia, A., Alfredsson, L. S., Olsson, T. P., Bottai, M., & Hillert, J. A. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1788 · Cited by 172
Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis
Lalive, P. H., Menge, T., Delarasse, C., Gaspera, B. D., Pham-Dinh, D., Villoslada, P., von Büdingen, H. ‐., & Genain, C. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510672103 · Cited by 173
Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis
Liu, C., Edwards, S., Gong, Q., Roberts, N., & Blumhardt, L. D. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.3.323 · Cited by 171
In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis
Rovaris, M. (2001) · Brain · doi:10.1093/brain/124.12.2540 · Cited by 173
Intracortical lesions: Relevance for new MRI diagnostic criteria for multiple sclerosis
Filippi, M., Rocca, M. A., Calabrese, M., Sormani, M. P., Rinaldi, F., Perini, P., Comi, G., & Gallo, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ff96f6 · Cited by 172
Superparamagnetic Iron Oxide Nanoparticles: Promises for Diagnosis and Treatment of Multiple Sclerosis
Mahmoudi, M., Sahraian, M. A., Shokrgozar, M. A., & Laurent, S. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn100100e · Cited by 176
Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
Bielekova, B., Howard, T., Packer, A. N., Richert, N. D., Blevins, G., Ohayon, J. M., Waldmann, T. A., McFarland, H. F., & Martinꝉ, R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.50 · Cited by 172
Importance of early treatment initiation in the clinical course of multiple sclerosis
Kavaliūnas, A., Manouchehrinia, A., Stawiarz, L., Ramanujam, R., Agholme, J., Hedström, A. K., Beiki, O., Glaser, A., & Hillert, J. A. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516675039 · Cited by 172
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis
Filippi, M., Horsfield, M. A., Adèr, H. J., Barkhof, F., Bruzzi, P., Evans, A. C., Frank, J. A., Grossman, R. I., McFarland, H. F., Molyneux, P. D., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430414 · Cited by 171
Cognitive impairment in three subtypes of multiple sclerosis
Denney, D. R., Sworowski, L. A., & Lynch, S. G. (2005) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2005.04.012 · Cited by 171
Fatigue and social impairment in multiple sclerosis: the role of patients' cognitive and behavioral responses to their symptoms.
Skerrett, T., & Moss-Morris, R. (2006) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.04.018 · Cited by 186
Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine
Parry, A. M. M. (2003) · Brain · doi:10.1093/brain/awg284 · Cited by 175
Chronic pain in a large community sample of persons with multiple sclerosis
Ehde, D. M., Gibbons, L. E., Chwastiak, L., Bombardier, C. H., Sullivan, M. D., & Kraft, G. H. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms939oa · Cited by 172
The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK
Orme, M. E., Kerrigan, J., Tyas, D., Russell, N., & Nixon, R. M. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00144.x · Cited by 170
The Multiple Sclerosis Functional Composite
Polman, C. H., & Rudick, R. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dbb571 · Cited by 170
Systematic, Evidence-Based Review of Exercise, Physical Activity, and Physical Fitness Effects on Cognition in Persons with Multiple Sclerosis
Sandroff, B. M., Motl, R. W., Scudder, M. R., & DeLuca, J. (2016) · Neuropsychology Review · doi:10.1007/s11065-016-9324-2 · Cited by 182
Social cognition in multiple sclerosis
Cotter, J., Firth, J., Enzinger, C., Kontopantelis, E., Yung, A. R., Elliott, R., & Drake, R. (2016) · Neurology · doi:10.1212/wnl.0000000000003236 · Cited by 181
Correlations between Structural CNS Damage and Functional MRI Changes in Primary Progressive MS
Filippi, M., Rocca, M. A., Falini, A., Caputo, D., Ghezzi, A., Colombo, B., Scotti, G., & Comi, G. (2002) · NeuroImage · doi:10.1006/nimg.2001.1023 · Cited by 170
Key issues in the diagnosis and treatment of multiple sclerosis
O'Connor, P. W. (2002) · Neurology · doi:10.1212/wnl.59.6_suppl_3.s1 · Cited by 170
Incontinence severity and QOL scales for fecal incontinence
Rockwood, T. H. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.10.057 · Cited by 170
Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality
Tyndall, A., Fassas, Α., Passweg, J. R., de Elvira, C. R., Attal, M., Brooks, P., Black, C., Durez, P., Finke, J., Forman, S. J., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701987 · Cited by 170
Cytokine mRNA expression in patients with multiple sclerosis and fatigue
Flachenecker, P., Bihler, I., Weber, F., Gottschalk, M., Toyka, K. V., & Rieckmann, P. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms991oa · Cited by 169
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis
Banwell, B., Reder, A. T., Krupp, L., Tenembaum, S. N., Eraksoy, M., Alexey, B., Pohl, D., Freedman, M. S., Schelensky, L., & Antonijevic, I. A. (2006) · Neurology · doi:10.1212/01.wnl.0000198257.52512.1a · Cited by 169
Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis
Meng, H., Johnston, B. C., Englesakis, M. F., Moulin, D. E., & Bhatia, A. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002110 · Cited by 169
Fatigue and sleep disturbance in multiple sclerosis
Kaynak, H., Altintas, A., Kaynak, D., Uyanik, Ö., Saip, S., Agaoglu, J., Önder, G., & Siva, A. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01499.x · Cited by 175
Pattern of hemodynamic impairment in multiple sclerosis: Dynamic susceptibility contrast perfusion MR imaging at 3.0 T
Adhya, S., Johnson, G., Herbert, J., Jaggi, H., Babb, J. S., Grossman, R. I., & Inglese, M. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.08.008 · Cited by 168
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples
Riazi, A. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.701 · Cited by 168
Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis
Rossi, S., Studer, V., Motta, C., Polidoro, S., Perugini, J., Macchiarulo, G., Giovannetti, A. M., Gutierrez, L. P., Calò, A., Colonna, I., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004411 · Cited by 175
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
Portaccio, E., Bellinvia, A., Fonderico, M., Pastò, L., Razzolini, L., Totaro, R., Spitaleri, D. L. A., Lugaresi, A., Cocco, E. E., ONOFRJ, M. C., et al. (2022) · Brain · doi:10.1093/brain/awac111 · Cited by 180
Gray and white matter volume changes in early RRMS
Tiberio, M., Chard, D., Altmann, D. R., Davies, G. R., Griffin, C., Rashid, W., Sastre‐Garriga, J., Thompson, A. J., & Miller, D. H. (2005) · Neurology · doi:10.1212/01.wnl.0000154526.22878.30 · Cited by 170
Differentiation of Multiple Sclerosis from Other Inflammatory Disorders and Cerebrovascular Disease: Value of Spinal MR Imaging
Bot, J. C. J., Barkhof, F., à Nijeholt, G. L., van Schaardenburg, D., Voskuyl, A. E., Ader, H. J., Pijnenburg, J. A. L., Polman, C. H., Uitdehaag, B. M. J., Vermeulen, E. G. J., et al. (2002) · Radiology · doi:10.1148/radiol.2231010707 · Cited by 168
The needs and experiences of caregivers of individuals with multiple sclerosis: a systematic review
McKeown, L. P., Porter-Armstrong, A. P., & Baxter, D. G. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr618oa · Cited by 168
Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms
Figved, N., Myhr, K. M., Larsen, J. P., & Aarsland, D. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.104216 · Cited by 168
The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis
Marrie, R. A., Zhang, L., Lix, L. M., Graff, L. A., Walker, J. R., Fisk, J. D., Patten, S. B., Hitchon, C. A., Bolton, J. M., Sareen, J., et al. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.12.007 · Cited by 169
Seven‐tesla phase imaging of acute multiple sclerosis lesions: A new window into the inflammatory process
Absinta, M., Sati, P., Gaitán, M. I., Maggi, P., Cortese, I. C. M., Filippi, M., & Reich, D. S. (2013) · Annals of Neurology · doi:10.1002/ana.23959 · Cited by 165
Unemployment in multiple sclerosis: the contribution of personality and disease
Strober, L., Christodoulou, C., Benedict, R., Westervelt, H., Melville, P., Scherl, W., Weinstock-Guttman, B., Rizvi, S., Goodman, A., & Krupp, L. (2012) · Multiple Sclerosis · doi:10.1177/1352458511426735 · Cited by 177
Clinical prognostic factors in multiple sclerosis: a natural history review
Degenhardt, A., Ramagopalan, S. V., Scalfari, A., & Ebers, G. C. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.178 · Cited by 167
Damage to the Optic Radiation in Multiple Sclerosis Is Associated With Retinal Injury and Visual Disability
Reich, D. S., Smith, S. A., Gordon‐Lipkin, E. M., Öztürk, A., Caffo, B. S., Balcer, L. J., & Calabresi, P. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.107 · Cited by 167
HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis
Hensiek, A. E. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.2.184 · Cited by 167
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
Nash, R. A., Hutton, G. J., Racke, M. K., Popat, U., Devine, S. M., Steinmiller, K. C., Griffith, L. M., Muraro, P. A., Openshaw, H., Sayre, P. H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003660 · Cited by 167
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis
Balcer, L. J., Raynowska, J., Nolan, R. C., Galetta, S. L., Kapoor, R., Benedict, R. H. B., Phillips, G. A., LaRocca, N. G., Hudson, L. D., & Rudick, R. A. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690822 · Cited by 167
Gait analysis in neurological populations: Progression in the use of wearables
Çelik, Y., Stuart, S., Woo, W. L., & Godfrey, A. (2020) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2020.11.005 · Cited by 173
Immersive virtual reality during gait rehabilitation increases walking speed and motivation: a usability evaluation with healthy participants and patients with multiple sclerosis and stroke
Winter, C., Kern, F., Gall, D., Latoschik, M. E., Pauli, P., & Käthner, I. (2021) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-021-00848-w · Cited by 183
Randomized multicenter trial of natalizumab in acute MS relapses
O'Connor, P. W., Goodman, A. D., Willmer–Hulme, A., Libonati, M., Metz, L., Murray, R. S., Sheremata, W. A., Vollmer, T. L., Stone, L. A., & the Natalizumab Multiple Sclerosis Trial Group (2004) · Neurology · doi:10.1212/01.wnl.0000128136.79044.d6 · Cited by 167
Safety and T Cell Modulating Effects of High Dose Vitamin D3 Supplementation in Multiple Sclerosis
Smolders, J., Peelen, E., Thewissen, M. M., Tervaert, J. W. C., Menheere, P. P. C. A., Hupperts, R., & Damoiseaux, J. G. M. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015235 · Cited by 166
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging
Mainero, C., Louapre, C., Govindarajan, S. T., Giannì, C., Nielsen, A. S., Cohen‐Adad, J., Sloane, J. A., & Kinkel, R. P. (2015) · Brain · doi:10.1093/brain/awv011 · Cited by 167
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
Mañé-Martínez, M. A., Olsson, B., Bau, L., Matas, E., Cobo‐Calvo, Á., Andréasson, U., Blennow, K., Romero-Pinel, L., Martínez‐Yélamos, S., & Zetterberg, H. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514549397 · Cited by 166
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
Burman, J., Iacobaeus, E., Svenningsson, A., Lycke, J., Gunnarsson, M., Nilsson, P., Vrethem, M., Fredrikson, S., Martin, C., Sandstedt, A. B., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307207 · Cited by 166
Disease modifying therapies for relapsing multiple sclerosis
Wingerchuk, D. M., & Weinshenker, B. G. (2016) · BMJ · doi:10.1136/bmj.i3518 · Cited by 174
Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population
Patten, S. B., Metz, L. M., & Reimer, M. A. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600210 · Cited by 171
Fatigue in multiple sclerosis: Interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability
van der Werf, S. P., Jongen, P. J., Nijeholt, G. J. L. À., Barkhof, F., Hommes, O. R., & Bleijenberg, G. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00251-2 · Cited by 166
MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic’s neuromyelitis optica
Filippi, M., Rocca, M. A., Moiola, L., Martinelli, V., Ghezzi, A., Capra, R., Salvi, F., & Comı, G. (1999) · Neurology · doi:10.1212/wnl.53.8.1705 · Cited by 166
THE USE OF OUTCOME MEASURES IN PHYSICAL MEDICINE AND REHABILITATION WITHIN EUROPE
Tennant, A. (2001) · Journal of Rehabilitation Medicine · doi:10.1080/165019701753236464 · Cited by 166
Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis
Llufriú, S., Sepúlveda, M., Blanco, Y., Marı́n, P., Moreno, B., Berenguer, J., Gabilondo, I., Martínez‐Heras, E., Solà‐Valls, N., Arnaiz, J. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113936 · Cited by 165
Thalamic Damage and Long-term Progression of Disability in Multiple Sclerosis
Rocca, M. A., Mesaroš, Š., Pagani, E., Sormani, M. P., Comi, G., & Filippi, M. (2010) · Radiology · doi:10.1148/radiol.10100326 · Cited by 165
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
Jones, J., Anderson, J. M., Phuah, C., Fox, E., Selmaj, K. W., Margolin, D. H., Lake, S. L., Palmer, J. P., Thompson, S. J., Wilkins, A., et al. (2010) · Brain · doi:10.1093/brain/awq176 · Cited by 167
Measuring fatigue in patients with multiple sclerosis: reproducibility, responsiveness and concurrent validity of three Dutch self-report questionnaires
Rietberg, M. B., van Wegen, E. E. H., & Kwakkel, G. (2010) · Disability and Rehabilitation · doi:10.3109/09638281003734458 · Cited by 162
Management of neurogenic bladder in patients with multiple sclerosis
Phé, V., Chartier-Kastler, E. J., & Panicker, J. N. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.53 · Cited by 168
Autologous Stem Cell Transplantation in Progressive Multiple Sclerosis—An Interim Analysis of Efficacy
Fassas, Α., Anagnostopoulos, Α., Kazis, A., Kapinas, K., Sakellari, I., Kimiskidis, V. Κ., Smias, C., Eleftheriadis, N., & Tsimourtou, V. (2000) · Journal of Clinical Immunology · doi:10.1023/a:1006686426090 · Cited by 165
Spasticity in Multiple Sclerosis
Barnes, M. P., Kent, R. M., Semlyen, J. K., & McMullen, K. (2003) · Neurorehabilitation and neural repair · doi:10.1177/0888439002250449 · Cited by 165
Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial
Tomassini, V., Pozzilli, C., Onesti, E., Pasqualetti, P., Marinelli, F., Pisani, A., & Fieschi, C. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.11.005 · Cited by 165
In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis
Granberg, T., Fan, Q., Treaba, C. A., Ouellette, R., Herranz, E., Mangeat, G., Louapre, C., Cohen-Adad, J., Klawiter, E. C., Sloane, J. A., et al. (2017) · Brain · doi:10.1093/brain/awx247 · Cited by 184

Authors: Kurtzke, J. F.
Affiliations: Georgetown University (US)
Corresponding author: Kurtzke, John F.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1983-11
Volume: 33
Issue: 11
Pages: 1444-1444
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.33.11.1444
OpenAlex: W2112165124
Cited by: 15,011
References: 13
Citations by year: 2026: 474 · 2025: 622 · 2024: 692 · 2023: 648 · 2022: 722 · 2021: 781 · 2020: 764 · 2019: 648 · 2018: 603 · 2017: 592 · 2016: 657 · 2015: 634 · 2014: 632 · 2013: 586 · 2012: 581
FWCI: 9.57
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
Keywords: multiple sclerosis, Expanded Disability Status Scale, disability assessment, neurological deficit, functional systems, pyramidal system, cerebellar function, brainstem, sensory impairment, bowel and bladder dysfunction, visual impairment
MeSH terms: Humans, Multiple Sclerosis, Nervous System Diseases, Neurologic Examination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks